These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 9726277)

  • 1. Sustained-release naltrexone for alcoholism treatment: a preliminary study.
    Kranzler HR; Modesto-Lowe V; Nuwayser ES
    Alcohol Clin Exp Res; 1998 Aug; 22(5):1074-9. PubMed ID: 9726277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone.
    Dunbar JL; Turncliff RZ; Dong Q; Silverman BL; Ehrich EW; Lasseter KC
    Alcohol Clin Exp Res; 2006 Mar; 30(3):480-90. PubMed ID: 16499489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence.
    Pettinati HM; Silverman BL; Battisti JJ; Forman R; Schweizer E; Gastfriend DR
    Alcohol Clin Exp Res; 2011 Oct; 35(10):1804-11. PubMed ID: 21575016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment.
    O'Malley SS; Garbutt JC; Gastfriend DR; Dong Q; Kranzler HR
    J Clin Psychopharmacol; 2007 Oct; 27(5):507-12. PubMed ID: 17873686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open-label pilot study of extended-release naltrexone to reduce drinking and driving among repeat offenders.
    Lapham SC; McMillan GP
    J Addict Med; 2011 Sep; 5(3):163-9. PubMed ID: 21844831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial.
    Galloway GP; Koch M; Cello R; Smith DE
    BMC Psychiatry; 2005 Apr; 5():18. PubMed ID: 15804355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.
    Krupitsky E; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Silverman BL
    Addiction; 2013 Sep; 108(9):1628-37. PubMed ID: 23701526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
    Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
    Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended-release naltrexone for treatment of alcohol dependence in primary care.
    Lee JD; Grossman E; DiRocco D; Truncali A; Hanley K; Stevens D; Rotrosen J; Gourevitch MN
    J Subst Abuse Treat; 2010 Jul; 39(1):14-21. PubMed ID: 20363090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended-release naltrexone plus medical management alcohol treatment in primary care: findings at 15 months.
    Lee JD; Grossman E; Huben L; Manseau M; McNeely J; Rotrosen J; Stevens D; Gourevitch MN
    J Subst Abuse Treat; 2012 Dec; 43(4):458-62. PubMed ID: 22985676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early treatment response in alcohol dependence with extended-release naltrexone.
    Ciraulo DA; Dong Q; Silverman BL; Gastfriend DR; Pettinati HM
    J Clin Psychiatry; 2008 Feb; 69(2):190-5. PubMed ID: 18348601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of naltrexone in the treatment of alcohol dependence: oral versus injectable delivery.
    Roozen HG; de Waart R; van den Brink W
    Eur Addict Res; 2007; 13(4):201-6. PubMed ID: 17851241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of extended-release naltrexone on holiday drinking in alcohol-dependent patients.
    Lapham S; Forman R; Alexander M; Illeperuma A; Bohn MJ
    J Subst Abuse Treat; 2009 Jan; 36(1):1-6. PubMed ID: 18775624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naltrexone: a review of existing sustained drug delivery systems and emerging nano-based systems.
    Goonoo N; Bhaw-Luximon A; Ujoodha R; Jhugroo A; Hulse GK; Jhurry D
    J Control Release; 2014 Jun; 183():154-66. PubMed ID: 24704710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes.
    Monti PM; Rohsenow DJ; Swift RM; Gulliver SB; Colby SM; Mueller TI; Brown RA; Gordon A; Abrams DB; Niaura RS; Asher MK
    Alcohol Clin Exp Res; 2001 Nov; 25(11):1634-47. PubMed ID: 11707638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended-release naltrexone (XR-NTX) attenuates brain responses to alcohol cues in alcohol-dependent volunteers: a bold FMRI study.
    Lukas SE; Lowen SB; Lindsey KP; Conn N; Tartarini W; Rodolico J; Mallya G; Palmer C; Penetar DM
    Neuroimage; 2013 Sep; 78():176-85. PubMed ID: 23571420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers.
    Johnson FK; Stark JG; Bieberdorf FA; Stauffer J
    Clin Ther; 2010 Jun; 32(6):1149-64. PubMed ID: 20637968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients.
    Pettinati HM; Gastfriend DR; Dong Q; Kranzler HR; O'Malley SS
    Alcohol Clin Exp Res; 2009 Feb; 33(2):350-6. PubMed ID: 19053979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics.
    Lucey MR; Silverman BL; Illeperuma A; O'Brien CP
    Alcohol Clin Exp Res; 2008 Mar; 32(3):498-504. PubMed ID: 18241321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vivitrex (Alkermes/Cephalon).
    Heading CE
    Curr Opin Investig Drugs; 2006 Jan; 7(1):81-8. PubMed ID: 16425675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.